The tumor cell‐derived matrix of lobular breast cancer: a new vulnerability

Invasive lobular carcinoma (ILC) of the breast is a very common disease. Despite its prevalence, these tumors are relatively understudied. One reason for this is a relative lack of models for ILC. This challenge was addressed by Brisken and colleagues through development of an intraductal injection‐based xenograft system for the study of ERα + breast cancers, including both ILC and more common invasive ductal carcinoma (IDC; Sflomos et al , 2016). In this issue of EMBO Molecular Medicine, the same group have applied intraductal injection‐based xenografts to identify novel tumor cell‐specific transcriptional signatures in ILC (Sflomos et al , 2021). In doing so they found overexpression of lysyl oxidase‐like 1 (LOXL1) to be both responsible for the frequently seen stiff collagen‐rich extracellular matrix of lobular breast cancer and essential for their robust growth and metastatic dissemination in vivo , thereby identifying a novel therapeutic target. Graphical Abstract Despite its prevalence, invasive lobular carcinoma (ILC) is relatively understudied. In their recent study, Brisken and colleagues apply intraductal injection based xenografts to characterize tumor‐cell specific transcriptional signatures in ILC and identify a novel therapeutic target.